{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:52:45Z","timestamp":1793649165500,"version":"4.5.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004106","name":"East China Normal University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004106","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118511","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T16:12:10Z","timestamp":1766247130000},"page":"118511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["HDAC and PI3K dual inhibitors in the treatment of cancers: Current status, trends, and solutions"],"prefix":"10.1016","volume":"304","author":[{"given":"Wanjing","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzhen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-6748","authenticated-orcid":false,"given":"Mingliang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118511_bib1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118511_bib2","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejmech.2025.118511_bib3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.lungcan.2011.02.019","article-title":"Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung","volume":"74","author":"Minamiya","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2025.118511_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(08)70004-4","article-title":"Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis","volume":"9","author":"Weichert","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.118511_bib5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118511_bib6","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1158\/1078-0432.CCR-07-0990","article-title":"Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo","volume":"14","author":"Weichert","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118511_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118511_bib8","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.ejmech.2025.118511_bib10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.ejmech.2025.118511_bib11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","article-title":"Development of PI3K inhibitors: lessons learned from early clinical trials","volume":"10","author":"Rodon","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118511_bib12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1756-8722-6-88","article-title":"Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics","volume":"6","author":"Akinleye","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118511_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.apsb.2016.07.006","article-title":"Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy","volume":"7","author":"Zhao","year":"2017","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118511_bib14","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1021\/acs.jmedchem.8b01492","article-title":"Class I PI3K clinical candidates and recent inhibitor design strategies: a medicinal chemistry perspective","volume":"62","author":"Garces","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","article-title":"Characterization of the novel and specific PI3K\u03b1 inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials","volume":"13","author":"Fritsch","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118511_bib16","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1021\/acs.jmedchem.8b01298","article-title":"Evolution of PI3K\u03b3 and \u03b4 inhibitors for inflammatory and autoimmune diseases","volume":"62","author":"Perry","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib17","first-page":"1364","article-title":"PI3K-\u03b4 and PI3K-\u03b3 inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem. Biol. (Oxford, U. K.)."},{"key":"10.1016\/j.ejmech.2025.118511_bib18","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2015.105","article-title":"The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL","volume":"29","author":"Balakrishnan","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118511_bib19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-021-01504-2","article-title":"Umbralisib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118511_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1078-0432.CCR-22-2939","article-title":"The oral PI3K\u03b4 inhibitor linperlisib for the treatment of relapsed and\/or refractory follicular lymphoma: a phase 2, single-arm, open-label clinical trial","volume":"29","author":"Wang","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118511_bib21","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \"activated PI3K\u03b4 syndrome\"-targeted therapy with the PI3K\u03b4 inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118511_bib22","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.18632\/oncotarget.659","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance","volume":"3","author":"McCubery","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118511_bib23","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/0008-5472.CAN-08-4765","article-title":"PI3k pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers","volume":"69","author":"Wee","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118511_bib24","doi-asserted-by":"crossref","first-page":"11937","DOI":"10.18632\/oncotarget.14442","article-title":"PI3K\/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor trichostatin A synergistically exert anti-tumor activity in breast cancer","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118511_bib25","doi-asserted-by":"crossref","first-page":"38879","DOI":"10.1074\/jbc.M505733200","article-title":"Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes","volume":"280","author":"Chen","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib26","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1158\/2159-8290.CD-17-0177","article-title":"mTOR and HDAC inhibitors converge on the TXNIP\/Thioredoxin pathway to cause catastrophic oxidative stress and regression of RAS-driven tumors","volume":"7","author":"Malone","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118511_bib27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/10799893.2020.1853159","article-title":"Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs","volume":"42","author":"Mehrpouri","year":"2022","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"10.1016\/j.ejmech.2025.118511_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: what are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118511_bib29","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/acschembio.6b01014","article-title":"Lysine deacetylation by HDAC6 regulates the kinase activity of AKT in human neural progenitor cells","volume":"12","author":"Iaconelli","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118511_bib30","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","article-title":"Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling","volume":"18","author":"Qian","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118511_bib31","doi-asserted-by":"crossref","first-page":"16658","DOI":"10.1021\/acs.jmedchem.3c01236","article-title":"Discovery of YSR734: a covalent HDAC inhibitor with cellular activity in acute myeloid leukemia and Duchenne muscular dystrophy","volume":"66","author":"Raouf","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib32","doi-asserted-by":"crossref","first-page":"14171","DOI":"10.1021\/acs.jmedchem.5c01677","article-title":"Advancements in hydrazide-based HDAC inhibitors: a review of recent developments and therapeutic potential","volume":"68","author":"Raucci","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib33","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1021\/acs.jmedchem.4c02373","article-title":"Exploring alternative zinc-binding groups in histone deacetylase (HDAC) inhibitors uncovers DS-103 as a potent ethylhydrazide based HDAC inhibitor with chemosensitizing properties","volume":"68","author":"Stopper","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib34","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/2767-9764.CRC-23-0250","article-title":"Concurrent targeting of HDAC and PI3K to overcome phenotypic heterogeneity of castration-resistant and neuroendocrine prostate cancers","volume":"3","author":"Zhang","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118511_bib35","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/cas.12002","article-title":"Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase\/phosphatidylinositol 3-kinase dual inhibitors","volume":"103","author":"Saijo","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2025.118511_bib36","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","article-title":"Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma:An open-label, dose escalation, phase I trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.118511_bib37","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/cas.13255","article-title":"Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase\/phosphatidylinositol 3-kinase dual inhibitor","volume":"108","author":"Saijo","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2025.118511_bib38","article-title":"Imidazopyrazines derivates as kinase inhibitors","author":"Fernandez","year":"2012","journal-title":"EP Patent 2524918A1"},{"key":"10.1016\/j.ejmech.2025.118511_bib39","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1021\/acs.jmedchem.6b00579","article-title":"Development of purine-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities","volume":"59","author":"Chen","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib40","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1158\/0008-5472.CAN-21-1547","article-title":"A dual PI3K\/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy","volume":"81","author":"Fan","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118511_bib41","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1021\/acs.jmedchem.7b01465","article-title":"Design, synthesis, and preclinical evaluation of fused pyrimidine-based hydroxamates for the treatment of hepatocellular carcinoma","volume":"61","author":"Chen","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib42","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/ci500493m","article-title":"Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602","volume":"54","author":"Poulsen","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118511_bib43","doi-asserted-by":"crossref","first-page":"52180","DOI":"10.1039\/C7RA08835C","article-title":"Design, synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-c]quinazoline derivatives as novel phosphatidylinositol 3-kinase and histone deacetylase dual inhibitors","volume":"7","author":"Wu","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.118511_bib44","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/cmdc.201600148","article-title":"Discovery and SAR of novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: identification of Copanlisib (BAY 80-6946)","volume":"11","author":"Scott","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118511_bib45","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1021\/acs.jmedchem.8b00416","article-title":"Discovery and optimization of 2-amino-4-methylquinazoline derivatives as highly potent phosphatidylinositol 3-kinase inhibitors for cancer treatment","volume":"61","author":"Lin","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib46","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1021\/acs.jmedchem.9b00390","article-title":"Design, synthesis, and biological evaluation of 4-methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-Kinases and histone deacetylases","volume":"62","author":"Zhang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib47","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1021\/acs.jmedchem.8b00189","article-title":"Kinase and histone deacetylase hybrid inhibitors for cancer therapy","volume":"62","author":"Luan","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115915","article-title":"Discovery of benzamide-based PI3K\/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells","volume":"262","author":"Deng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116015","article-title":"Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K\/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia","volume":"264","author":"Zhang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib50","article-title":"Design, synthesis and bioactive evaluation of novel quinoline-linked sulfonamide-pyridine derivatives as PI3K\/HDAC dual-target inhibitors","volume":"301","author":"Sun","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117658","article-title":"Discovery of hydrazide-based PI3K\/HDAC dual inhibitors with enhanced pro-apoptotic activity in lymphoma cells","volume":"292","author":"Hou","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib52","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1021\/acs.jmedchem.0c00193","article-title":"Design, synthesis, and biological evaluation of quinazolin-4-one-based hydroxamic acids as dual PI3K\/HDAC inhibitors","volume":"63","author":"Thakur","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib53","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1074\/jbc.M114.634683","article-title":"Structural, biochemical, and biophysical characterization of Idelalisib binding to phosphoinositide 3-Kinase delta","volume":"290","author":"Somoza","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib54","doi-asserted-by":"crossref","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","article-title":"Histone Deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability","volume":"288","author":"Lauffer","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117028","article-title":"Identification of PI3K\/HDAC dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid tumors: building HDAC6 potency in a Quinazolinone-based PI3K\u03b4-selective template","volume":"73","author":"Li","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117852","article-title":"Design, synthesis, and biological evaluation of novel PI3K\u03b4\/HDAC6 dual inhibitors for the treatment of non-hodgkin\u2019s lymphoma","volume":"296","author":"Zuo","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29062-w","article-title":"Buparlisib is a brain penetrable pan-PI3K inhibitor","volume":"8","author":"Gooijer","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118511_bib58","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1016\/j.bmcl.2010.10.021","article-title":"Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors","volume":"20","author":"Pecchi","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118511_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117067","article-title":"Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K\/HDAC dual inhibitors","volume":"74","author":"Wang","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib60","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1021\/acs.jmedchem.5b01525","article-title":"Design, synthesis, and pharmacological evaluation of novel N-acylhydrazone derivatives as potent histone deacetylase 6\/8 dual inhibitors","volume":"59","author":"Rodrigues","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib61","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nchembio.2140","article-title":"Structural insights into HDAC6 tubulin deacetylation and its selective inhibition","volume":"12","author":"Miyake","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118511_bib62","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118511_bib63","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/cmdc.201900716","article-title":"Design, synthesis, and pharmacological evaluation of first-in-class multitarget N-acylhydrazone derivatives as selective HDAC6\/8 and PI3Kalpha inhibitors","volume":"15","author":"Rodrigues","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118511_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129462","article-title":"Discovery of (S)-N1-(thiazol-2-yl) pyrrolidine-1,2-dicarboxamide derivatives targeting PI3Ka\/HDAC6 for the treatment of cancer","volume":"94","author":"Zhang","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118511_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112844","article-title":"Paradigm shift of \u2033classical\u2033 HDAC inhibitors to \u2033hybrid\u2033 HDAC inhibitors in therapeutic interventions","volume":"209","author":"Vaidya","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib66","doi-asserted-by":"crossref","first-page":"8977","DOI":"10.1021\/acs.jmedchem.0c00491","article-title":"Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112831","article-title":"Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment","volume":"208","author":"Peng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib68","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1021\/acs.jmedchem.4c02269","article-title":"Discovery of D-ring-contracted artemisinin as a potent hydrophobic tag for targeted protein degradation","volume":"68","author":"Qing","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib69","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1021\/acs.jmedchem.4c02021","article-title":"Monoselective Histone deacetylase 6 PROTAC degrader shows in vivo tractability","volume":"68","author":"Garcha","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118511_bib70","doi-asserted-by":"crossref","first-page":"13793","DOI":"10.1021\/acs.jmedchem.5c00674","article-title":"Development and characterization of the first selective class IIb histone deacetylase degraders","volume":"68","author":"Zhai","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:17:35Z","timestamp":1773929855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":70,"alternative-id":["S0223523425012760"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118511","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDAC and PI3K dual inhibitors in the treatment of cancers: Current status, trends, and solutions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118511"}}